India's role in affordable cell and gene therapies, including CAR-T, and the need for a mission mode approach.
ThePrint on MSN6d
2nd ‘living drug’ against blood cancer gets regulatory nod. All about Qartemi, made in IndiaTherapy will cost Rs 35 to 50 lakh. India sees around 1.20 lakh new blood cancer cases and over 70,000 deaths annually from ...
India Today on MSN2d
India approves living drug to treat blood cancer: All about Qartemi and how it worksThe second CAR-T cell therapy, Qartemi, has been approved by India's drug regulator. Qartemi is a "living drug" for blood ...
A "living drug" Qartemi has been approved for blood cancer patients in India who suffer from an advanced or relapsed stage of ...
Here's a list of buy/sell recommendations for today from three analysts: Ankush Bajaj, Raja Venkatraman, and MarketSmith ...
Synthetic biology startup Fermbox works in an asset-light business model and has raised $2.5 Mn so far to build its tech ...
Immuneel Therapeutics launches affordable CAR-T therapy Qartemi for B-cell Non-Hodgkin Lymphoma, aiming to revolutionize ...
Union Finance Minister Nirmala Sitharaman is all set to present her eighth budget on February 1. Tax simplification, ...
Kiran Mazumdar-Shaw, Chairperson of major drugmaker Biocon Ltd., urged the government to eliminate tax on drugs for cancer treatment and for chronic and rare diseases, ahead of the budget 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback